TABLE 1

Effect of 14-Day Lasting Rimcazole Treatment on Biodistribution of ¹⁸F-FDG

	SUV			Tissue to plasma
Tissue	Control	Rimcazole	P	Control	Rimcazole	P
Brain	1.19 ± 0.15	1.57 ± 0.28	NS	7.00 ± 0.45	7.12 ± 1.06	NS
Tumor	0.97 ± 0.17	1.36 ± 0.21	NS	5.57 ± 0.40	6.22 ± 0.88	NS
Lungs	1.90 ± 0.28	2.30 ± 0.09	NS	11.38 ± 1.59	10.84 ± 0.82	NS
Kidney	2.91 ± 0.13	3.03 ± 0.69	NS	18.16 ± 2.39	13.62 ± 2.39	NS
Liver	0.37 ± 0.03	0.72 ± 0.10	<0.02	2.34 ± 0.38	3.34 ± 0.46	NS
Bone	0.58 ± 0.07	0.63 ± 0.10	NS	3.46 ± 0.27	2.82 ± 0.29	NS
Colon	2.47 ± 0.57	3.00 ± 0.62	NS	13.84 ± 1.39	13.35 ± 2.32	NS
Duodenum	2.40 ± 0.31	2.94 ± 0.56	NS	14.30 ± 1.55	13.50 ± 2.52	NS
Fat	0.58 ± 0.26	0.83 ± 0.28	NS	3.44 ± 1.74	3.63 ± 0.97	NS
Heart	26.71 ± 2.80	28.71 ± 5.49	NS	171.25 ± 34.68	131.23 ± 18.64	NS
Ileum	2.13 ± 0.19	2.62 ± 0.47	NS	13.11 ± 1.70	11.78 ± 1.80	NS
Muscle	0.31 ± 0.07	0.25 ± 0.02	NS	1.69 ± 0.23	1.17 ± 0.10	0.06
Pancreas	0.46 ± 0.06	0.86 ± 0.10	<0.01	2.71 ± 0.30	4.06 ± 0.54	0.06
Plasma	0.17 ± 0.02	0.22 ± 0.03	NS	1.00	1.00	NS
RBC	0.16 ± 0.02	0.31 ± 0.06	0.07	0.99 ± 0.10	1.42 ± 0.30	NS
Spleen	1.81 ± 0.32	2.08 ± 0.28	NS	10.42 ± 0.81	9.60 ± 0.99	NS
Trachea	0.97 ± 0.15	1.38 ± 0.22	NS	6.36 ± 1.71	6.30 ± 0.87	NS
Urine	39.81 ± 7.06	38.92 ± 20.57	NS	236.43 ± 37.40	164.02 ± 70.73	NS

SUVs and tissue-to-plasma ratios of ¹⁸F with blood glucose correction, approximately 2 h after injection of ¹⁸F-FDG. Data were obtained from control (n = 5) and rimcazole-treated (n = 5) mice, respectively, after PET scan of Figure 4.
NS = not significant.